{"id":"combination-bivalent-bnt162b2-and-bnt162b2-omi","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pain medications (e.g., ibuprofen, naproxen)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants (e.g., heparin, enoxaparin)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents (e.g., clopidogrel, prasugrel)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Thrombolytics (e.g., alteplase, tenecteplase)","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Live vaccines","action":"Avoid","effect":"Reduced efficacy of vaccine"},{"drug":"Immunosuppressants (e.g., corticosteroids, cyclosporine)","action":"Monitor","effect":"Reduced efficacy of vaccine"},{"drug":"Interferons (e.g., interferon-alpha, interferon-beta)","action":"Monitor","effect":"Reduced efficacy of vaccine"},{"drug":"Other vaccines","action":"Avoid","effect":"Reduced efficacy of vaccine"}],"commonSideEffects":[{"effect":"Injection site pain","drugRate":"13.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":673,"trialsReporting":1},{"effect":"Fatigue","drugRate":"7.5%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":383,"trialsReporting":1},{"effect":"Headache","drugRate":"5.3%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":267,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"5.1%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":258,"trialsReporting":1},{"effect":"Myalgia","drugRate":"4.9%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":248,"trialsReporting":1},{"effect":"Chills","drugRate":"4.8%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":243,"trialsReporting":1},{"effect":"Lymphadenopathy","drugRate":"2.8%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":141,"trialsReporting":1},{"effect":"Pain","drugRate":"2.7%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":139,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"1.1%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":58,"trialsReporting":1},{"effect":"Nausea","drugRate":"1.1%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":54,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Vomiting (VOMITING)","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site pain (PAIN)","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING)","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"SARS-CoV-2 test positive","drugRate":"0.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Eye pruritis","drugRate":"0.0%","organSystem":"Eye disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Syncope","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Seasonal allergy","drugRate":"0.0%","organSystem":"Immune system disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Ear infections","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Attention deficit-hyperactivity disorder","drugRate":"0.0%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Dysmenorrhoea","drugRate":"0.0%","organSystem":"Reproductive system and breast disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Epistaxis","drugRate":"0.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Rhinitis allergic","drugRate":"0.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site swelling","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Dry mouth","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Axillary pain","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Swelling","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Corneal abrasion","drugRate":"0.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Gout","drugRate":"0.0%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Bone swelling","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Disturbance in attention","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Abnormal dreams","drugRate":"0.0%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Anxiety","drugRate":"0.0%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Panic disorder","drugRate":"0.0%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Dry throat","drugRate":"0.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Pruritus","drugRate":"0.0%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Haematochezia","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Feeling abnormal","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Onychomycosis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1},{"effect":"Skin infection","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":5080,"totalAffected":0,"trialsReporting":1}],"contraindications":["Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.","Anaphylaxis following administration of the vaccine.","Acute severe febrile illness or acute infection.","Thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.","Immunosuppressed individuals.","Pregnant women."],"specialPopulations":{"Pregnancy":"There is limited experience with use of COMIRNATY in pregnant women. Administration of COMIRNATY in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus. No data are available yet regarding the use of COMIRNATY (Bivalent) during pregnancy.","Geriatric use":"text","Paediatric use":"The safety and efficacy of COMIRNATY (Bivalent) in children aged less than 6 months has not yet been established. COMIRNATY (Bivalent) should be administered intramuscularly (see section 6.6). The preferred site for injection is the deltoid muscle of the upper arm.","Renal impairment":"text","Hepatic impairment":"text"},"seriousAdverseEvents":[{"event":"Acute myocardial infarction","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Atrial fibrillation","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Appendicitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Prostate cancer","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Syncope","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Nephrolithiasis","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.1%"},{"event":"Sickle cell anaemia with crisis","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiac failure","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Coronary artery disease","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Myocardial infarction","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Myopericarditis","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Coronary artery insufficiency","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pericarditis","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Tachycardia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Ventricular extrasystoles","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Goitre","detail":"Endocrine disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Colitis","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Gastric fistula","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Gastrointestinal haemorrhage","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hiatus hernia","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Intestinal perforation","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Lower gastrointestinal haemorrhage","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pancreatitis acute","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Small intestinal obstruction","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Upper gastrointestinal haemorrhage","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Chest pain","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Death","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Non-cardiac chest pain","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Sudden cardiac death","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Bile duct stone","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=combination-bivalent-bnt162b2-and-bnt162b2-omi","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:38:09.674083+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:15.855966+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:09.745760+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=combination-bivalent-bnt162b2-and-bnt162b2-omi","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:16.491601+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Spike glycoprotein vaccine antigen","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:17.925151+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650429/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:17.589944+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:32:32.672812+00:00"}},"allNames":"combination (bivalent) bnt162b2 and bnt162b2 omi","offLabel":[],"timeline":[],"aiSummary":"Pfizer's combination-bivalent-bnt162b2-and-bnt162b2-omi is a marketed COVID-19 vaccine developed by Pfizer Inc. It works by targeting the SARS-CoV-2 virus. The vaccine is indicated for individuals 12 years of age and older for prevention of COVID-19, and for individuals 5 years of age and older. This vaccine is clinically differentiated from others due to its combination of two bivalent components. It has achieved significant commercial success, generating $63.6B in revenue. There are no pipeline developments mentioned.","brandName":"Combination (Bivalent) BNT162b2 and BNT162b2 OMI","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 virus","novelty":"best-in-class","modality":"vaccine","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"The vaccine's mechanism of action involves the presentation of SARS-CoV-2 antigens to the immune system, which triggers a specific response to the virus. This response is mediated by the production of antibodies and the activation of immune cells. The vaccine's combination of two bivalent components provides enhanced protection against COVID-19."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"+7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"~","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=combination-bivalent-bnt162b2-and-bnt162b2-omi","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=combination-bivalent-bnt162b2-and-bnt162b2-omi","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:32:33.997185+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"BNT162b1","company":"BioNTech/Pfizer","advantage":"Alternative vaccine candidate to BNT162b2"},{"name":"BNT162b2 (30 µg)","company":"BioNTech/Pfizer","advantage":"Lower dose option compared to BNT162b2 (60 µg)"},{"name":"BNT162b2 OMI (30 µg)","company":"BioNTech/Pfizer","advantage":"Lower dose option compared to BNT162b2 OMI (60 µg)"},{"name":"BNT162b2 OMI (60 µg)","company":"BioNTech/Pfizer","advantage":"Higher dose option compared to BNT162b2 OMI (30 µg)"},{"name":"BNT162b2 (60 µg)","company":"BioNTech/Pfizer","advantage":"Higher dose option compared to BNT162b2 (30 µg)"},{"name":"Combination of BNT162b2 and BNT162b2 OMI (15 µg each)","company":"BioNTech/Pfizer","advantage":"Lower dose combination option compared to BNT162b2 and BNT162b2 OMI (30 µg each)"},{"name":"Combination of BNT162b2 and BNT162b2 OMI (30 µg each)","company":"BioNTech/Pfizer","advantage":"Higher dose combination option compared to BNT162b2 and BNT162b2 OMI (15 µg each)"}],"genericName":"combination-bivalent-bnt162b2-and-bnt162b2-omi","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04955626","phase":"PHASE3","title":"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-07-01","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":16372},{"nctId":"NCT05596734","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-10-28","conditions":"Influenza, Human, COVID-19","enrollment":1019},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT05543356","phase":"PHASE3","title":"COVID-19 Fourth Dose Study in Australia","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-02","conditions":"COVID-19","enrollment":0}],"_emaApprovals":[{"date":"","name":"Combination (Bivalent) BNT162b2 and BNT162b2 OMI","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4650429","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4650429"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"95.3","nctId":"NCT04955626","phase":"PHASE3","pValue":"","ciLower":"89.5","ciUpper":"98.3","endpoint":"SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population","enrollment":16372}],"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"vaccine","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:32:33.997185+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}